ArticleBMJ open2026

Development of an externally controlled trial from a single-arm study to assess first-line immunochemotherapy in advanced large cell neuroendocrine lung carcinomas: a study protocol from the FIRST-NEC GFPC 01-2022 trial.

Aymeric De Montfort et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.